Androgens as therapy for androgen receptor-positive castration-resistant prostate cancer

NCU Institutional Repository > 生醫理工學院 > 生命科學系 > 期刊論文 > Item 987654321/50797

請使用永久網址來引用或連結此文件: http://ir.lib.ncu.edu.tw/handle/987654321/50797

題名:	Androgens as therapy for androgen receptor-positive castration-resistant prostate cancer
作者:	Chuu,CP;Kokontis,JM;Hiipakka,RA;Fukuchi,J;Lin,HP;Lin,CY;Huo,C;Su,LC
貢獻者:	生命科學系
關鍵詞:	CELL-CYCLE ARREST;DEPRIVATION THERAPY;ATHYMIC MICE;TUMOR-GROWTH;TESTOSTERONE REPLACEMENT;CARDIOVASCULAR-DISEASE;GENE AMPLIFICATION;PROTEIN EXPRESSION;PROSPECTIVE TRIAL;LNCAP CELLS
日期:	2011
上傳時間:	2012-03-27 18:10:20 (UTC+8)
出版者:	國立中央大學
摘要:	Prostate cancer is the most frequently diagnosed non-cutaneous tumor of men in Western countries. While surgery is often successful for organ-confined prostate cancer, androgen ablation therapy is the primary treatment for metastatic prostate cancer. However, this therapy is associated with several undesired side-effects, including increased risk of cardiovascular diseases. Shortening the period of androgen ablation therapy may benefit prostate cancer patients. Intermittent Androgen Deprivation therapy improves quality of life, reduces toxicity and medical costs, and delays disease progression in some patients. Cell culture and xenograft studies using androgen receptor (AR)-positive castration-resistant human prostate cancers cells (LNCaP, ARCaP, and PC-3 cells over-expressing AR) suggest that androgens may suppress the growth of AR-rich prostate cancer cells. Androgens cause growth inhibition and G1 cell cycle arrest in these cells by regulating c-Myc, Skp2, and p27(Kip) via AR. Higher dosages of testosterone cause greater growth inhibition of relapsed tumors. Manipulating androgen/AR signaling may therefore be a potential therapy for AR-positive advanced prostate cancer.
關聯:	JOURNAL OF BIOMEDICAL SCIENCE
顯示於類別:	[生命科學系] 期刊論文

文件中的檔案:

檔案	描述	大小	格式	瀏覽次數
index.html		0Kb	HTML	595	檢視/開啟

在NCUIR中所有的資料項目都受到原著作權保護.

社群 sharing

資料載入中.....